UBS Group AG decreased its position in GeneDx Holdings Corp. (NASDAQ:WGS – Free Report) by 40.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 89,190 shares of the company’s stock after selling 60,599 shares during the quarter. UBS Group AG’s holdings in GeneDx were worth $11,600,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds also recently bought and sold shares of WGS. ARK Investment Management LLC bought a new stake in GeneDx in the 3rd quarter worth approximately $48,157,000. Franklin Resources Inc. lifted its position in GeneDx by 101.9% in the third quarter. Franklin Resources Inc. now owns 681,381 shares of the company’s stock valued at $73,412,000 after purchasing an additional 343,954 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. bought a new stake in GeneDx in the third quarter valued at approximately $31,488,000. Amova Asset Management Americas Inc. bought a new stake in GeneDx in the third quarter valued at approximately $31,444,000. Finally, Assenagon Asset Management S.A. lifted its position in GeneDx by 1,358.7% in the fourth quarter. Assenagon Asset Management S.A. now owns 205,895 shares of the company’s stock valued at $26,779,000 after purchasing an additional 191,780 shares during the last quarter. Institutional investors own 61.72% of the company’s stock.
GeneDx Price Performance
Shares of GeneDx stock opened at $40.75 on Friday. The company has a quick ratio of 2.95, a current ratio of 3.09 and a debt-to-equity ratio of 0.38. The company has a market cap of $1.21 billion, a PE ratio of -15.21 and a beta of 2.06. The business has a 50 day moving average of $64.01 and a 200 day moving average of $102.00. GeneDx Holdings Corp. has a 52 week low of $32.21 and a 52 week high of $170.87.
Insider Activity
In other GeneDx news, CEO Katherine Stueland sold 46,933 shares of the firm’s stock in a transaction dated Thursday, March 26th. The shares were sold at an average price of $63.17, for a total value of $2,964,757.61. Following the completion of the sale, the chief executive officer directly owned 91,514 shares in the company, valued at $5,780,939.38. This trade represents a 33.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Keith A. Meister acquired 533,758 shares of the stock in a transaction on Thursday, May 7th. The stock was bought at an average price of $37.86 per share, with a total value of $20,208,077.88. Following the completion of the acquisition, the director directly owned 3,761,908 shares of the company’s stock, valued at $142,425,836.88. This trade represents a 16.53% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last quarter, insiders have purchased 1,725,941 shares of company stock worth $74,034,301 and have sold 104,028 shares worth $7,377,165. 29.60% of the stock is owned by insiders.
GeneDx News Roundup
Here are the key news stories impacting GeneDx this week:
- Positive Sentiment: Director Keith A. Meister kept buying shares, including 165,000 shares on May 13, 140,000 shares on May 14, and 46,273 shares on May 15, signaling strong insider confidence in GeneDx’s outlook and helping support the stock. Insider trade filing
- Neutral Sentiment: GeneDx received an average brokerage recommendation of “Moderate Buy,” suggesting Wall Street still sees upside despite the recent volatility. Brokerage recommendation article
- Negative Sentiment: A legal update from Pomerantz LLP said it is investigating claims on behalf of GeneDx investors, adding overhang from possible shareholder litigation after the company’s recent results. Pomerantz investigation article
- Negative Sentiment: Another law firm, Levi & Korsinsky, announced a securities investigation tied to GeneDx’s Q1 revenue miss and reduced full-year guidance, reinforcing concerns that the post-earnings selloff may not be over. Levi & Korsinsky investigation article
- Negative Sentiment: An analyst note cut GeneDx’s price target sharply to $98.94, highlighting a more cautious view after the company’s disappointing quarter. Price target cut article
Analysts Set New Price Targets
Several analysts have weighed in on WGS shares. Zacks Research downgraded GeneDx from a “strong-buy” rating to a “hold” rating in a research report on Friday, April 24th. Wall Street Zen downgraded GeneDx from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Weiss Ratings reiterated a “sell (d)” rating on shares of GeneDx in a research report on Wednesday, January 21st. BTIG Research lowered their price objective on GeneDx from $170.00 to $90.00 and set a “buy” rating for the company in a research report on Tuesday, May 5th. Finally, Guggenheim lowered their price objective on GeneDx from $100.00 to $70.00 and set a “buy” rating for the company in a research report on Tuesday, May 5th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $96.43.
Check Out Our Latest Research Report on WGS
GeneDx Profile
GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.
Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.
Featured Articles
- Five stocks we like better than GeneDx
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
Want to see what other hedge funds are holding WGS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GeneDx Holdings Corp. (NASDAQ:WGS – Free Report).
Receive News & Ratings for GeneDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx and related companies with MarketBeat.com's FREE daily email newsletter.
